FTH
insider transactionsSensei Biotherapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·C
President and CEO
—
761 sh
Own New
-
Exercise·C
President and CEO
—
761.4K sh
Own New
-
Exercise·C
Director
—
45 sh
Own New
-
Exercise·C
Director
—
44.8K sh
Own New
-
Grant·A
Director
$0
25.0K sh
Own New
-
Grant·A
Director
$0
25.0K sh
Own New
-
Grant·A
Chief Operating Officer
$0
1.2M sh
Own New
-
Grant·A
President and CEO
—
136.9K sh
Own New
-
Grant·A
President and CEO
—
12.3K sh
Own New
-
Grant·A
President and CEO
—
761 sh
Own +0%
-
Grant·A
Chief Operating Officer
—
56.7K sh
Own New
-
Grant·A
Chief Operating Officer
—
92.5K sh
Own New
-
Grant·A
Chief Operating Officer
—
809.8K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Anand Kiran Parikh KEY | Exercise C | 761 | — |
| Jun 15, 2026 | Anand Kiran Parikh KEY | Exercise C | 761.4K | — |
| Jun 15, 2026 | Stephen M. Hahn | Exercise C | 45 | — |
| Jun 15, 2026 | Stephen M. Hahn | Exercise C | 44.8K | — |
| Jun 12, 2026 | Saira Ramasastry | Grant A | 25.0K | $0 |
| Jun 12, 2026 | Stephen M. Hahn | Grant A | 25.0K | $0 |
| Feb 19, 2026 | Anand Kiran Parikh | Grant A | 1.2M | $0 |
| Feb 17, 2026 | Anand Kiran Parikh KEY | Grant A | 136.9K | — |
| Feb 17, 2026 | Anand Kiran Parikh KEY | Grant A | 12.3K | — |
| Feb 17, 2026 | Anand Kiran Parikh KEY | Grant A | 761 | — |
| Feb 17, 2026 | Anand Kiran Parikh | Grant A | 56.7K | — |
| Feb 17, 2026 | Anand Kiran Parikh | Grant A | 92.5K | — |
| Feb 17, 2026 | Anand Kiran Parikh | Grant A | 809.8K | — |
About FTH insider trading
This page tracks insider transactions for Sensei Biotherapeutics, Inc. (FTH) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.